Literature DB >> 16538929

Morbidity and mortality in patients on dialysis: the impact of hemoglobin levels.

Mary Brattich1.   

Abstract

Clinical reports supporting an association between hemoglobin (Hb) levels, morbidity, and mortality were a strong part of the dataset used by the National Kidney Foundation in recommending a target Hb level of 11 to 12 g/dL in patients on dialysis. This article provides an overview of the potential link between Hb correction and improvements in morbidity and mortality in patients on dialysis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16538929

Source DB:  PubMed          Journal:  Nephrol Nurs J        ISSN： 1526-744X            Impact factor:   0.959


  3 in total

1.  Comorbidity burden at dialysis initiation and mortality: A cohort study.

Authors:  Alwyn T Gomez; Bryce A Kiberd; J Patrick Royston; Talal Alfaadhel; Steven D Soroka; Brenda R Hemmelgarn; Karthik K Tennankore
Journal:  Can J Kidney Health Dis       Date:  2015-09-08

2.  JR-131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double-Blinded, Parallel-Group Phase 3 Study.

Authors:  Shinichi Nishi; Masayuki Yamada; Kazuhiko Tsuruya; Ikuto Masakane; Hidetomo Nakamoto
Journal:  Ther Apher Dial       Date:  2019-08-21       Impact factor: 1.762

3.  Long-Term Safety and Efficacy of JR-131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study.

Authors:  Shinichi Nishi; Masayuki Yamada; Kazuhiko Tsuruya; Ikuto Masakane; Hidetomo Nakamoto
Journal:  Ther Apher Dial       Date:  2019-08-19       Impact factor: 1.762
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.